Key Insights

Highlights

Success Rate

33% trial completion

Treatment Research

9 treatments under study, led by Laboratory Biomarker Analysis

Research Leaders

5 sponsors active, led by National Cancer Institute (NCI)

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

66.7%

2 terminated out of 3 trials

Success Rate

33.3%

-53.3% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results33% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (2)

Trial Status

Terminated2
Completed1

Trial Success Rate

33.3%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05104099Phase 2Completed

Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia

NCT02140021Not ApplicableTerminated

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

NCT03267680Phase 2Terminated

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Showing all 3 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis2
  • Cyclophosphamide1
  • Indomethacin1
  • Multivitamin1
  • Irx21

Active Sponsors

  • National Cancer Institute (NCI)2
  • Brooklyn ImmunoTherapeutics, LLC1
  • M.D. Anderson Cancer Center1
  • University of Southern California1
  • Institut de Cancérologie de Lorraine1

Top Investigators

Related Conditions

  • Vulvar Intraepithelial Neoplasia2
  • Stage Iv Vaginal Cancer Ajcc V81
  • Stage Iva Cervical Cancer Ajcc V81
  • Stage Iva Vulvar Cancer Ajcc V81
  • Stage Iv Cervical Cancer Ajcc V81

Activity Timeline